Sarcoma News

The FDA’s Oncologic Drugs Advisory Committee, or ODAC, today voted 12-3 that the benefits of pexidartinib outweigh the risks for the treatment of adults with tenosynovial giant cell tumor not amenable to surgical resection.

Hyperprogressive disease did not appear to be related to clinically significant adverse events, age, tumor type or type of immunotherapy among patients with solid tumors in early-phase trials, according to results of a retrospective study published in Cancer.

Cancer screening in presymptomatic patients with Li-Fraumeni syndrome appeared cost-effective for third-party payers, according to results of a study published in Pediatric Blood and Cancer.

ATLANTA — Adults and children with advanced HER2-positive sarcoma safely tolerated and derived clinical benefit from lymphodepletion chemotherapy followed by infusions of autologous HER2-targeted chimeric antigen receptor T cells, according to results of a phase 1 trial presented at American Association for Cancer Research Annual Meeting.

About 1 in 1,000 patients with breast cancer who underwent radiotherapy later developed radiotherapy-associated angiosarcoma, a serious complication for which surgery alone may be the most effective treatment, according to study results in a research letter published in JAMA Oncology.

Steven A. Rosenberg, MD, PhD, will receive the 2019 Szent-Györgyi Prize for Progress in Cancer Research.

Concomitant administration of gastric acid-suppressant therapy with pazopanib significantly reduced PFS and OS in patients with soft tissue sarcoma, according to an analysis of data from phase 2 and phase 3 randomized trials published in Clinical Cancer Research.

Immune checkpoint inhibitor therapy appeared to be a safe, effective treatment for patients with advanced-stage cancer and HIV infection, according to a systematic review published in JAMA Oncology.

The fossilized femur of a 240 million-year-old reptile showed evidence of osteosarcoma, according to a research letter published in JAMA Oncology.

ASCO has named progress in treating rare cancers as the cancer Advance of the Year, recognizing major research advances that generated new treatments for patients with rare, difficult-to-treat cancers, such as desmoid tumors and uterine serous carcinoma, the society announced in a press release.